Skip to content

The investigation of blood concentrations of beta-cryptoxanthin associated with ingestion of Ripe Kumquats "Tama-Tama". : A randomization open-label, non-eating simultaneous control comparison group study.

The investigation of blood concentrations of beta-cryptoxanthin associated with ingestion of Ripe Kumquats "Tama-Tama". : A randomization open-label, non-eating simultaneous control comparison group study. - The clinical trial for blood concentrations of beta-cryptoxanthin associated with ingestion of Ripe Kumquats "Tama-Tama"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024868
Enrollment
12
Registered
2016-11-18
Start date
2016-11-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults.

Interventions

per day for seven days. The subjects take ten Ripe Kumquats &quot
per day for seven days. The subjects don&#39
for seven days.

Sponsors

University of Miyazaki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects who are judged as healthy by self-reported health questionnaire. 2. Subjects who have no abnormality in clinical problems by screening tests. 3. Subjects who agree to participate in this study with a written informed consent after receiving sufficient explanation relating to this study.

Exclusion criteria

Exclusion criteria: 1. Subjects who have respiratory, gastrointestinal, hepatic/gallbladder/pancreatic, hematologic, renal, endocrine, cardiovascular and/or mental disease, or who have history of those diseases. 2. Subjects who have a serious injury or surgical history within 12 weeks prior to this study. 3. Pre- or post-menopausal women having obvious changes in physical condition. 4. Subjects who are at risk of having allergic reaction to citrus foods including kumquat. 5. Subjects who have history of allergic reaction to foods or drugs which needs its treatment or who have possibility of the reaction. 6. Subjects who are heavy smoker (more than 21 cigarettes per day), or alcohol addicts (more than 20g per day alcohol), or alcohol or drug dependency or who have possibility of the dependency. 7. Subjects who regularly take drugs, foods for specified health uses, foods with function claims and/or supplements, etc. which would affect this study. 8. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within four weeks or blood components within two weeks prior to this study. 9. Pregnant or lactating women or women expect to be pregnant during this study. 10. Subjects who have cognitive disorder or who have possibility of the disorder. 11. Subjects who participate and take the study drug in other clinical trials within 12 weeks prior to this study. 12. Subjects who are judged as unsuitable for this study by the principal investigator or subinvestigators.

Design outcomes

Primary

MeasureTime frame
Serum concentrations of beta-cryptoxanthin on the first day, 3rd day, 5th day, 8th day and five weeks after ingestion of Ripe Kumquat "Tama-Tama".

Secondary

MeasureTime frame
1. Natural killer cell activity 2. Interleukin-6 values 3. Fatigue related scales 4. QOL scales(SF-36) 5. Adverse events. (These secondary outcomes are assessed on the first day, 3rd day, 5th day, 8th day and five weeks after ingestion of Ripe Kumquat "Tama-Tama" except adverse events.)

Countries

Japan

Contacts

Public ContactYasuji Arimura

University of Miyazaki Clinical research support center, University of Miyazaki hospital

yasuji_arimura@med.miyazaki-u.ac.jp0985-85-9577

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026